GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (FRA:0N6A) » Definitions » Float Percentage Of Total Shares Outstanding

TME Pharma NV (FRA:0N6A) Float Percentage Of Total Shares Outstanding : 0.00% (As of Mar. 03, 2025)


View and export this data going back to 2018. Start your Free Trial

What is TME Pharma NV Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, TME Pharma NV's float shares is 0.00 Mil. TME Pharma NV's total shares outstanding is 94.12 Mil. TME Pharma NV's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, TME Pharma NV's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, TME Pharma NV's Institutional Ownership is 2.03%.

TME Pharma NV Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

TME Pharma NV's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/94.12
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TME Pharma NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (FRA:0N6A) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
XPAR:ALOPM XPAR:ALVIO XPAR:ALTAO XPAR:ALBPS XPAR:ALTHX XPAR:ALVET XPAR:GNRO XPAR:ALINT XPAR:POXEL XPAR:ALMDP VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
ALTME:France 0N6A:Germany
Address
Max-Dohrn-Street 8-10, Berlin, DEU, 10589
Website
https://www.tmepharma.com
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).

TME Pharma NV Headlines

No Headlines